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ABSTRACT
Objective: To test the hypothesis that the Health
Utilities Index Mark III (HUI3) and the SF-6D, based
on the SF-36, generate similar health state values, and
to test and compare their discriminant validity and
responsiveness.
Methods: The HUI3 and SF-36 were administered to 331
patients enrolled in a double-blind, multinational phase
III clinical trial in patients undergoing percutaneous
coronary intervention before hospital discharge and
6 months thereafter.
Results: The mean SF-6D baseline health state score was
0.67 compared to the HUI3 of 0.63 with r of 0.616 and
intraclass correlation coefﬁcient of 0.40. The relationship
was nonlinear with greatest divergence found at the lower
levels of health. Both measures were found to agree with
known differences in health and to be responsive to
changes over time. Nevertheless, disagreement resulted in
different estimates of change from baseline (0.08 vs.
0.154).
Conclusion: Both measures deployed in the present study
were found to have discriminant validity, and to be
responsive to changes over time in coronary artery disease
conditions. Nevertheless, the measures generated different
estimates of health state values for this patient population.
These differences might in part be the consequence of the
health status descriptive system for the HUI that may have
been more in line with the hospitalized state than that for
the SF-6D. These ﬁndings seemed to indicate that meas-
ures deployed are not interchangeable for use in cost-
utility analysis. More head-to-head comparisons between
these two measures are needed to further deﬁne and com-
pare relationships in different patient populations.
Keywords: clinical trial, coronary artery disease, discrimi-
nant validity, health state preference.
Introduction
The ever-increasing demands on health-care systems
have stimulated much interest in the cost-
effectiveness (CE) of health-care interventions [1–
3]. An important technique for assessing CE has
been cost utility analysis, which incorporates pref-
erences for different health states by using quality
adjusted life-years (QALYs). The health state values
used to derive QALYs can be obtained from a vari-
ety of sources including clinicians and other third
parties, directly from patients, or from one of a
number of multiattribute utility instruments [4].
Various governmental bodies concerned with
appraising new technologies, and the Washington
Cost-Effectiveness Panel [5] have recommended the
use of social values and advocated the use of
preference-based measures of health such as the
Health Utility Index (HUI) [6].
The  Health  Utilities  Index  Mark  III  (HUI3)  is
a  multiattribute system that consists of eight
attributes: hearing, vision, speech, ambulation, dex-
terity, emotion, cognition, and pain. Each attribute
consists of multiple levels of functioning varying
between normal and severely impaired. A combina-
tion of levels across the attributes constitutes a
health state. The HUI3 has been valued using data
from a survey of 504 members of the general pop-
ulation. Multiattribute utility theory (MAUT) was
used to derive the ﬁnal algorithm for scoring all
states deﬁned by the HUI3 [6]. The MAUT substan-
tially reduced the valuation task by making simpli-
ﬁed assumptions about the relationship between
dimensions.
The SF-6D is a preference-based single index of
the SF-36. The SF-36 is a generic health status meas-
ure that consists of a 36-item self-report inventory,
which assesses health-related limitations in eight
domains: physical functioning, role limitations
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because of physical functioning, bodily pain, gen-
eral health perceptions, vitality, social functioning,
role limitations because of emotional problems, and
mental health [7–9]. The SF-6D is a preference-
based single index derived from the SF-36 via a
multiattribute system similar in design to the HUI3
[10]. The SF-6D is composed of six multilevel
dimensions of health, which together deﬁne 18,000
states of health. A selection of 249 health states
deﬁned by the SF-6D has been valued by a repre-
sentative sample of the UK general population
(n = 611). Regression models were estimated to pre-
dict the single index scores for all health states
deﬁned by the SF-6D [10].
The last decade has seen a proliferation of pref-
erence-based measures [11]. Such a proliferation
created the need to further investigate the issue of
interchangeability between preference-based meas-
ures. Investigating the interchangeability is best
accomplished using head-to-head comparisons; yet,
to our knowledge, very few head-to-head compari-
sons have been undertaken to date. Moreover, head-
to-head comparison of the HUI3 and the SF-6D is
nonexistent. This article presents the ﬁrst attempt to
compare these two instruments using a coronary
artery diseased (CAD) population enrolled in a mul-
tinational, randomized, double-blind clinical trial.
Objectives of the Study
The overall goal of this study was to compare the
calculated HUI3 and the SF-6D values in CAD
patient population. The speciﬁc objectives of the
research were to:
1. test the hypothesis that the two instruments
generate the same health state values;
2. understand the patterns and sources of conver-
gence and/or divergence of values calculated for
the two measures;
3. compare the discriminant validity of both
measures; and
4. compare the responsiveness of the measures to
changes over time.
Methods
The Evaluation of Xemiloﬁban in Controlling
Thrombotic Events (EXCITE) trial was initially
conducted using a peri-operative intravenously
administered investigational drug. The efﬁcacy of
the drug in decreasing the incidence of death, non-
fatal myocardial infarction (MI), and the need for
urgent revascularization during percutaneous coro-
nary intervention (PCI), namely balloon angioplasty
with or without stent placement, was investigated.
The trial was prospective, controlled, randomized,
double-blind, and lasted up to 182 days. The com-
pleted trial showed the investigational drug lacking
the required clinical efﬁcacy [12]. Three hundred
thirty-one patients of the EXCITE study from par-
ticipating centers in Canada and the United States
completed the following health status measures in
the order presented: the chronic (i.e., 4-week recall
of the SF-36), the 15-item self-administered (4-week
recall version of the HUI3), and the Seattle angina
Questionnaire (SAQ). Measurements were taken at
baseline and after 6 months, or when a patient
exited the study before its completion. Baseline
health status measures were administered after the
patient underwent inpatient PCI and before leaving
the hospital.
Patients provided demographic, medical, and
cardiovascular history at screening. Patients who
completed the health status measures met the study
inclusion and exclusion criteria for the trial. The
former included males and females between the ages
of 21 and 80, having known CAD, and being eligi-
ble for an approved PCI. Investigators were encour-
aged to enroll patients with high and multiple risks
including conditions such as unstable angina or
recent MI, speciﬁed types of saphenous vein graft
target lesion (lesion), having diabetes mellitus, an
anticipated need for placement of one or more
stent(s), and multivessel disease (MVDIS).
Demographics and risk characteristics of this
patient study population indicated that 80% of the
study population was men under the age of 55
(66%). As per study protocol, identiﬁed clinical
risks in this group of patients included the follow-
ing; urgent admission to the hospital (65%), having
diabetes (25%), having saphenous vein graft lesion
(lesion, 54%), having MVDIS (45%), having left
arterial disease (LAD, 39%), having multiple revas-
cularization (MULREVA, 31%), and having under-
gone stent placement (23%). Sixteen percent of the
study patients experienced daily angina pain.
Statistical Analysis
The aim of the analysis was fourfold: 1) to test the
null hypothesis that the HUI3 and the SF-6D gen-
erate similar preference-based health index scores;
2) to examine the possible causes for any diver-
gence (disagreements); 3) to examine the discrimi-
nant validity of the two instruments across
groupings of patients with varying degrees of CAD-
related severity; and 4) to compare the responsive-
ness of the instruments to changes between baseline
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and follow-up assessments. Weights used to derive
utilities from the HUI3 were those by Feeny and
colleagues [6]. Weights used to derive utilities from
the SF-36 were based on the algorithm calculated
by Brazier and Colleagues [10]. The following sec-
tions describe procedures for testing each of the
hypotheses.
Agreement between HUI3 and the SF-6D
The extent of agreement between the two instru-
ments was examined in a number of ways. First, the
size and the statistical signiﬁcance (P £ 0.05) of the
mean differences were calculated for those who
completed both instruments at baseline and follow-
up assessments. Second, correlation between the
two indexes was measured using Pearson correla-
tion coefﬁcient. To account for the fact that calcu-
lating correlation between instruments purporting
to measure similar things may be viewed as a poor
measure of agreement [13], the intraclass correla-
tion coefﬁcient (ICC) was also used as a measure of
agreement. A coefﬁcient of zero indicates no agree-
ment, while a coefﬁcient of one indicates perfect
agreement [14]. Finally, the pattern of agreement
was examined graphically by plotting values
obtained for the two indexes.
Possible Causes of  Divergence or Disagreement
Potential sources of disagreement between the two
indexes may come from 1) differences in the health
status descriptive systems for the measures; 2) from
their valuation methods that consisted of transfor-
mation from visual analog scale (VAS) to standard
gamble (SG) for the HUI versus directly elicited SG
for the SF-6D; or 3) their methods of interpolation.
While it would not be possible to examine the con-
sequences of the latter two potential sources of dif-
ference, it was possible to compare the distribution
of responses across the two descriptive systems, and
to identify any possible ceiling or ﬂoor effects. Ceil-
ing or ﬂoor effects were examined by the existence
of signiﬁcant numbers at the top or bottom of the
scale of each dimension. The degree of association
between the dimensions was measured using the
Spearman’s correlation coefﬁcient.
The Discriminant Validity of  the Two Instruments
The distributions of responses of CAD patients by
dimensions were compared to those of the general
population samples from the UK for the SF-6D [15]
and from Canada for the HUI3 [16]. These general
population samples, although limited in size and the
degree of representativeness, were judged adequate
for comparison with this study sample of CAD
patients. Distributions of responses were compared
using the chi-square test.
Known group differences were examined within
the CAD patients for the following: gender, age
group (<55 or ≥55), MULREVA, emergency status
(at the time of hospital admission where the admis-
sion was considered as urgent if the patient was
admitted to the hospital suffering from an MI or
unstable angina, or not urgent if the patient was
admitted to the hospital with stable angina). The age
group categories, while somewhat arbitrary, were
guided by the frequency distribution of those over
and under 55 which is in line with normative pop-
ulation categories for the SF-36, and an earlier study
dealing with the economics of CAD intervention
reporting median age for these patients to be 55 [17].
The discriminant validity of the two instruments
was also examined across the different severity
groups deﬁned by clinical risk groupings including
lesion type, presence of diabetes, left ventricular
ejection fraction (LVEF <0.30), placement of a
stent, MVDIS, LAD, and lesions [12]. As a result of
the empiric ﬁnding of having a small number of
patients in each risk group, the discriminant validity
of the two measures was examined by grouping risk
factors. Patients were grouped into three risk
groups: group 1 (no risk), group 2 (1–2 risk factors)
and group 3 (more than 2 risk factors). Severity was
also examined using item 3 of the SAQ; this item
gauges the number of anginal episodes experienced
by the patient in the past 4 weeks. Responses were
grouped according to whether or not patients expe-
rienced pain on daily, weekly, or monthly basis.
Responsiveness
Responsiveness was examined by comparing the
calculated  mean  change  from  baseline  to  ﬁnal
visit for each of the two indexes. Responsiveness
was also examined using the Standardized Mean
Response of the changes obtained by dividing the
means over the standard deviation of the change
[18]. It was anticipated that most, if not all, patients
would experience improvement over time. To gauge
the impact of potential improvement in the patients’
CAD severity on mean changes over time, a more
detailed analysis was undertaken. Analysis entailed
examination of the responsiveness over time in
changes to self-reported angina (as better, same, or
worse), by time spent, between assessment, in  the
coronary care unit (CCU), and by having experi-
enced a bleed.
It is important to state that no attempt was made
to apriori deﬁne clinically important differences, as
the issue, in the mind of most researchers is not yet,
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settled [19]. Moreover, in the context of economic
evaluation, minimally important differences depend
on their implications for the incremental cost effec-
tiveness ratio of the intervention.
Results
Completion of the two instruments was high with
the SF-6D achieving 91% (307) and the HUI3
achieving 97% (325). Analyses of baseline data and
changes from baseline values were based on the 300
patients (89%) who provided complete data for
both instruments. Table 1 displays the demographic
and risk characteristics of the present study popu-
lation. Sixty-six percent of the study population was
younger than 55 years; 45% have MVDISD, and
65% had an urgent admission to the hospital.
Table 2 provides descriptive statistics for the eight
domains of the SF-36, the SF-6D, and the HUI3.
The mean baseline (± SD) for the SF-6D health state
value was 0.67 ± 0.12 as compared to the HUI3
with 0.63 ± 0.29; the mean difference was statisti-
cally signiﬁcant (P £ 0.05).
The mean values for the two measures signiﬁ-
cantly correlated with a Pearson correlation coefﬁ-
cient of 0.62 and an ICC of 0.40. The cause of the
apparently low ICC could be seen from the plot of
HUI3 to SF-6D (Fig. 1). The plot showed a substan-
tial deviation from the line that would be indicative
of the perfect agreement between the two measures
(i.e., the 45-degree line from the origin of 0.4 to 1).
The Spearman rank correlations between the SF-
6D dimensions of bodily pain, physical functioning
and mental health and the corresponding HUI
dimensions of pain, ambulation and emotion were
calculated at 0.628, 0.378, and 0.422, respectively.
All correlations were statistically signiﬁcant (P £
0.05).
The distributions of responses across the dimen-
sions of each instrument and their relationships
were examined to explore reasons for divergence of
scores between the two measures. It was found that
the HUI3 had a substantial proportion of its
respondents at the ceiling of its dimensions, with
50% or more appearing in the top level for ﬁve
dimensions and the remainder falling between 11.3
and 46%. While the range of proportions for the
SF-6D at the ceiling was 4.7% to 34.7%, it had
large ﬂoor effects with 1.7% to 39.5% at the lowest
level. This is compared to the HUI3 with 0% to
7.7%. The largest ﬂoor effects in the SF-6D
occurred in the role dimension (39.5%).
Discriminant Validity
The discriminant validity of the two measures was
ﬁrst tested by comparing the frequency distribution
of responses by dimensions in this patient popula-
tion with the respective general population samples,
from which original weights were obtained [15,16].
Results (not displayed) indicated that the study pop-
Table 1 Baseline demographic and risk characteristics
Variable Absolute frequency Total (%)
Age ≥55 113 0.34
Females 68 0.20
With diabetes 82 0.25
With lesion 179 0.54
LVEFD 6 0.02
MVDISD 149 0.45
STENSD 75 0.23
VGRAFTD 13 0.04
Urgent admission 217 0.65
MULREVA 104 0.31
LAD 128 0.39
Daily angina pain 53 0.16
Abbreviations: LAD, left arterial disease; Lesion, saphenous vein graft lesion;
LVEFD, left ventricular ejection fraction <30; MULREVA, multilevel/multiseg-
ment revascularization; MVDISD, multivessel disease; STENTS, placement of
more than one stent; VGRAFTD, saphenous vein graft.
Table 2 Descriptive statistics for the various domains of  the
SF-36, the SF-6D and the HUI-III at baseline
SF-36 domains n Min Max Mean SD
Vitality 326 0.0 100.0 48.32 22.77
General health 323 5.0 100.0 62.48 20.94
Mental health 330 8.0 100.0 70.67 19.55
Pain 332 0.0 100.0 61.71 26.03
Physical functioning 331 0.0 100.0 62.40 25.82
Role emotional 321 0.0 100.0 59.81 42.92
Role physical 324 0.0 100.0 38.89 42.42
Social functioning 332 0.0 100.0 69.01 27.20
SF-6D 296 0.27 0.96 0.67 0.12
HUI-III 325 -0.21 1.00 0.63 0.29
Figure 1 Relationship between the distribution of  the HUI3 and the
SF-6D utility scores.
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ulation distributions for all dimensions were signif-
icantly different from the general population for
both instruments, using the chi-square test (P £
0.05).
The discriminant validity was further tested by
calculating the mean baseline values for the SF-6D
and HUI3, across gender, age group (<55 or ≥55),
self-report angina pain, risk group, and emergency
status (Table 3). For both measures, the patterns of
changes were in the expected direction, except for
age where patients under the age of 55 showed
slightly lower scores than patients 55 years of age or
older. One possible explanation might be that CAD
in the younger patients might be more severe.
Females had a statistically signiﬁcantly lower score
than males on the SF-6D only, using independent
sample t-test (£0.01). Using one-way ANOVA, there
were signiﬁcant differences (£0.01) in both meas-
ures between those patients who experienced
monthly angina pain as compared to the ones who
had experienced pain more frequently. For the SF-
6D only, there was also a statistically signiﬁcant dif-
ference (£0.05) between those who were admitted
urgently to the hospital versus those who did not,
using the independent t-test.
Responsiveness
One hundred and eighty-four patients completed
baseline and follow-up measurements for both
instruments. As seen in Table 4, the mean change in
scores between baseline and follow-up was 0.083
(SD 0.13) for the SF-6D and 0.152 (SD 0.28) for the
HUI3. Mean changes from baselines were signiﬁ-
cantly different between the two measures (£0.05).
The mean changes translated into Standardized
Response Means of 0.66 and 0.54 for the SF-6D
and HUI3, respectively. The correlation between
changes in scores for the two measures was 0.54.
Both measures were signiﬁcantly associated with
changes in angina pain between baseline and fol-
low-up, using one-way ANOVA (£0.01). While the
reduction in score was similar in those whose pain
got worse, those who got better did so by 0.20 on
the HUI3 compared to 0.11 for the SF-6D. Time
spent in CCU was associated with reduction in
scores for both instruments, but this difference was
only signiﬁcant, using the independent t-test, for the
SF-6D (P £ 0.05). Bleeding events did not result in
lesser improvement in either of the two instruments.
Discussion
The study compared the application of two utility
measures in patients with CAD using HUI3 and the
SF-36-derived utility measure, SF-6D. The SF-6D
preference-based algorithm has been developed to
estimate health state values from the SF-36 for use
in calculating QALYs [10]. Previous attempts to
estimate  health  values  from  the  SF-36,  such  as
that  used in the Beaver Dam study and a study by
Nicholl and colleagues, represented indirect
approaches [20–22]. The algorithm used in this
study represented a direct attempt to value the SF-
36 [10].
The added interest in comparing the SF-6D to the
HUI3 is that preferences for both measures were
based on the same variant of SG, albeit that of the
HUI3 was via a transformation of the VAS. This
study, to the best of our knowledge, was the ﬁrst
Table 3 SF-6D and HUI-III scores by demographics and
CAD risks (variables) at baseline
Variables n SF-6D* HUI-III*
Age
<55 years 106 0.664 ± 0.14 0.609 ± 0.32
≥55 years 194 0.668 ± 0.12 0.638 ± 0.28
Gender
Male 244 0.679 ± 0.12 0.641 ± 0.29
Female 56 0.615 ± 0.11‡ 0.569 ± 0.33
Angina pain
Daily 77 0.601 ± 0.11 0.495 ± 0.32
Weekly 171 0.671 ± 0.12 0.635 ± 0.29
Monthly 48 0.733 ± 0.12‡ 0.806 ± 0.21‡
Risk group
1 55 0.678 ± 0.15 0.639 ± 0.35
2 184 0.670 ± 0.12 0.633 ± 0.30
3 58 0.647 ± 0.10 0.602 ± 0.24
Urgent status
Yes 196 0.657 ± 0.13 0.606 ± 0.31
No 104 0.685 ± 0.11† 0.668 ± 0.27
*Mean ± SD; †P £ 0.05; ‡P £ 0.01.
Note: CAD risk variables: Angina pain measured using item 3 of  SAQ dealing
with the number of  occasions having angina pain over last 4 weeks; risk groups:
1) no risk; 2) having one or two 2 risk factors; 3) having more than 2 risk factors;
urgent refers to hospitalization status upon admission. Statistical comparisons
were made using the following analyses: 1) independent sample t-test (age, gen-
der and urgent status); 2) one-way ANOVA (angina and risk groups).
Table 4 Change scores from baseline for SF-6D and HUI3
overall and by severity
SF-6D* HUI3*
Overall (n = 184) 0.083 ± 0.13 0.152 ± 0.28†
Angina pain
Worse -0.05 ± 0.09 -0.04 ± 0.30
Same 0.05 ± 0.11 0.08 ± 0.27
Better 0.11 ± 0.13‡ 0.20 ± 0.28‡
Time in CCU
Yes 0.07 ± 0.12 0.14 ± 0.26
No 0.10 ± 0.13† 0.17 ± 0.29
Bleeding event(s)
Yes 0.09 ± 0.12 0.17 ± 0.26
No 0.07 ± 0.13 0.13 ± 0.31
*Mean ± SD; †P £ 0.05; ‡P £ 0.01.
Note: Statistical comparisons were made using the following analyses: 1) inde-
pendent sample t-test (Overall, bleeding events and time in CCU); 2) one-way
ANOVA (angina pain).
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comparison of the values generated by these two
measures and their discriminant properties in CAD
patients within the context of clinical trial setting.
There was a small, but signiﬁcant, difference in
the mean health state values between the SF-6D and
the HUI3 at baseline. This small variation at base-
line may have masked a considerable disagreement
between the two instruments, as shown by the ICC
and plots. The HUI3 exceeded the SF-6D for most
observations below a mean score of 0.6; differences
were more pronounced for lower values. These
cross-sectional differences were shown to contrib-
ute to a twofold variation in the magnitude of
change found in these patients over time (0.15 for
the HUI3 and 0.08 for the SF-6D). These ﬁndings
are in line with a recent study that compared the
two measures [23]. In this study, the mean SF-6D
and HUI3 utilities in patients with intermittent clau-
dication, before treatment, were the same (0.66 vs.
0.66). After treatment, all utilities showed improve-
ment from before treatment (P < 0.05); the gain in
utilities from treatment was lower when using the
SF-6D [23].
This disagreement may be due in part to differ-
ences in the health status descriptive classiﬁcation of
the two measures. A comparison of the distribution
of responses over the individual dimensions demon-
strated that most of the HUI3 responses congre-
gated in the top level of each scale, whereas the SF-
6D had larger responses in the lowest level. These
ﬂoor and ceiling effects would have contributed to
the disagreement seen. Disagreements may have
also resulted from the use of a transformed VAS
score to estimate SG values with HUI3 compared to
direct SG values for the SF-6D. The use of multipli-
cative function for the HUI3, as compared to the
additive model estimated using statistical methods
for the SF-6D, may have also been responsible for
some of the differences encountered.
Despite the differences seen, there was little
disparity between the two instruments in terms of
their discriminant properties. Both produced the
expected distributions of values across demographic
and risk variables, and correlated signiﬁcantly with
other subjective assessments of health including that
of the investigator and the patients’ own assess-
ment. Although mean differences between groups
were somewhat smaller for the SF-6D, these differ-
ences were associated with smaller standard devia-
tions and hence resulted in more statistical
signiﬁcance as compared to those calculated for the
HUI3. Both measures were also comparable in
terms of overall responsiveness and for changes in
angina pain.
When compared to the general population,
results seemed to provide some evidence for the dis-
criminant validity of these two instruments in those
dimensions where CAD and its related comorbidi-
ties, for example, diabetes, were expected to impact.
Moreover, the score distributions by age, gender,
angina pain risk group, and urgency (for the SF-6D)
support the construct validity of these instruments.
Findings presented in this study indicated that
these two utility indexes seemed to measure similar
constructs. Nevertheless, measures are not inter-
changeable for the purpose of measuring QALYs or
in CUA. Similar conclusions were drawn from a
recent study that compared ﬁve utility measures
including both the HUI and the SF-6D. Authors
concluded that utility measures used in their study
were not interchangeable, and cautioned that the
lack of interchangeability has potential implications
for the interpretation and comparability of health
outcome studies and economic analyses [24]. Simi-
larly, a recent comparison of ﬁve utility measures
led authors to conclude that at present no single
utility measure can be considered as the “gold
standard.” Authors advised researchers to select an
instrument sensitive to the health states under inves-
tigation [25]. Findings reported in the present study
seemed to echo these authors’ conclusions.
Limitations of the Study
There were a number of limitations to this study.
First, results were based on a clinical trial-based
sample of patients, which may not be totally repre-
sentative of the CAD patient population or the
general population. Also, instruments were
administered in a hospital setting under circum-
stances that were not ideal for health status assess-
ment, given the transient nature of the in-hospital
health state. This limitation may have impacted the
SF-6D with questions related to role limitations and
social functioning, rather than the HUI3 with its
within skin attributes. The SF-36 from which the
SF-6D was derived adopts a relatively inclusive def-
inition of health that includes social functioning.
One would have anticipated that the recall period
of 28 days would have captured patients’ function-
ing, before hospitalization event. Results, however,
indicated that the SF-6D was disadvantaged by the
hospital setting where baseline measurement was
taken and by the timing of the administration. The
HUI3, on the other hand, had adopted a relatively
narrower “within the skin” approach to health sta-
tus that focuses on physical and emotional dimen-
sion of health status, and excludes social
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functioning because it takes place “outside the
skin” [26,27]. The fact that the HUI items do not
directly ask patients to gauge their physical or
social functioning may have made it more relevant
to this group of hospitalized CAD patients. In inter-
preting the differences observed between these two
measures, it is conceivable that in this group of
patients and the health circumstances leading to
their being hospitalized, social functioning and
interaction may not have been on the radar screen.
Nevertheless, this scenario may not extend to other
CAD patients or to other patient groups living in
their community.
In spite of these limitations, this study provides
useful insight into the relationship between the SF-
6D and the HUI3, and a benchmark for future stud-
ies in this area. Further head-to-head comparisons
of these two measures, and other health states
valuation measures, are needed across different
conditions.
This research was funded by Pharmacia Corporation.
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